{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:02:00Z","timestamp":1788883320114,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1124\/jpet.119.258178","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T21:15:38Z","timestamp":1558127738000},"page":"197-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial"],"prefix":"10.1016","volume":"370","author":[{"given":"Giorgio","family":"Minotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierantonio","family":"Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Armento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Annibali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Salvatorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Reggiardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.258178_bib1","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/sj.bjc.6605095","article-title":"Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer","volume":"100","author":"Altena","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.119.258178_bib2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","article-title":"Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties","volume":"110","author":"Antzelevitch","year":"2004","journal-title":"Circulation"},{"key":"10.1124\/jpet.119.258178_bib3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.119.258178_bib4","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2015.04.013","article-title":"Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study","volume":"65","author":"Armstrong","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/jpet.119.258178_bib5","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1161\/CIRCULATIONAHA.111.048520","article-title":"Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo","volume":"124","author":"Bishu","year":"2011","journal-title":"Circulation"},{"key":"10.1124\/jpet.119.258178_bib6","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment","volume":"32","author":"Borlaug","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1124\/jpet.119.258178_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000486761","article-title":"Early diastolic dysfunction after cancer chemotherapy: primary endpoint results of a multicenter cardio-oncology study [published correction appears in Chemotherapy (2018) 63:64]","volume":"63","author":"Calabrese","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1124\/jpet.119.258178_bib8","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1111\/bph.13791","article-title":"Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction","volume":"174","author":"Cappetta","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.258178_bib9","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","article-title":"American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects","volume":"25","author":"Carver","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.119.258178_bib11","doi-asserted-by":"crossref","first-page":"H1923","DOI":"10.1152\/ajpheart.00173.2009","article-title":"Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion","volume":"297","author":"Dhalla","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/jpet.119.258178_bib12","series-title":"Ranexa: Summary of Product Characteristics","first-page":"1","year":"2016"},{"key":"10.1124\/jpet.119.258178_bib13","series-title":"Cancer and the Heart","first-page":"11","article-title":"Anthracycline cardiotoxicity: clinical aspects, recognition, monitoring, treatment, and prevention","author":"Ewer","year":"2013"},{"key":"10.1124\/jpet.119.258178_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40265-012-0005-z","article-title":"Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"key":"10.1124\/jpet.119.258178_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MNM.0000000000000941","article-title":"Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy","volume":"40","author":"Klein","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1124\/jpet.119.258178_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pbiomolbio.2005.07.001","article-title":"Oxygen sensing in the body","volume":"91","author":"Lahiri","year":"2006","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1124\/jpet.119.258178_bib17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s002100000378","article-title":"Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system","volume":"363","author":"L\u00e9tienne","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.119.258178_bib18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/CIRCRESAHA.111.258251","article-title":"Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity","volume":"110","author":"Lovelock","year":"2012","journal-title":"Circ Res"},{"key":"10.1124\/jpet.119.258178_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/hc0502.103010","article-title":"Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings","volume":"105","author":"Lubien","year":"2002","journal-title":"Circulation"},{"key":"10.1124\/jpet.119.258178_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1124\/jpet.118.249235","article-title":"Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy","volume":"366","author":"Menna","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.258178_bib21","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1021\/tx800002r","article-title":"Cardiotoxicity of antitumor drugs","volume":"21","author":"Menna","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/jpet.119.258178_bib22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1124\/jpet.118.253104","article-title":"The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines","volume":"367","author":"Menna","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.258178_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/jpet.113.204057","article-title":"Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs","volume":"346","author":"Minotti","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.258178_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.119.258178_bib25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2009.09.068","volume":"55","author":"Morrow","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/jpet.119.258178_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.echo.2008.11.023","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"22","author":"Nagueh","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1124\/jpet.119.258178_bib27","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1124\/jpet.119.258178_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1113\/jphysiol.2013.264242","article-title":"CrossTalk opposing view: the late sodium current is not an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction)","volume":"592","author":"Papp","year":"2014","journal-title":"J Physiol"},{"key":"10.1124\/jpet.119.258178_bib29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2009.06.067","article-title":"Treatment of heart failure with normal ejection fraction: an inconvenient truth!","volume":"55","author":"Paulus","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/jpet.119.258178_bib30","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in Cardio-Oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.119.258178_bib31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.amjcard.2004.09.025","article-title":"Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris","volume":"95","author":"Rousseau","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1124\/jpet.119.258178_bib32","doi-asserted-by":"crossref","first-page":"e004311","DOI":"10.1161\/CIRCHEARTFAILURE.117.004311","article-title":"Relaxation and the role of calcium in isolated contracting myocardium from patients with hypertensive heart disease and heart failure with preserved ejection fraction","volume":"10","author":"Runte","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1124\/jpet.119.258178_bib33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.2014-0500","article-title":"Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: incidence and predictors","volume":"20","author":"Serrano","year":"2015","journal-title":"Oncologist"},{"key":"10.1124\/jpet.119.258178_bib34","series-title":"PBNP Datasheet, updated information, 2012-10 version","year":"2012"},{"key":"10.1124\/jpet.119.258178_bib35","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.yjmcc.2012.01.018","article-title":"The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors","volume":"52","author":"Springer","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"10.1124\/jpet.119.258178_bib36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccl.2008.06.002","article-title":"Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias","volume":"26","author":"Stone","year":"2008","journal-title":"Cardiol Clin"},{"key":"10.1124\/jpet.119.258178_bib37","series-title":"Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA\/BE Studies","first-page":"1","year":"2012"},{"key":"10.1124\/jpet.119.258178_bib38","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0","first-page":"1","year":"2017"},{"key":"10.1124\/jpet.119.258178_bib39","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jcmg.2009.09.006","article-title":"A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images","volume":"2","author":"Venkataraman","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1124\/jpet.119.258178_bib40","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap","year":"2003","journal-title":"Heart"},{"key":"10.1124\/jpet.119.258178_bib41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.yjmcc.2010.08.018","article-title":"Paclitaxel accelerates spontaneous calcium oscillations in cardiomyocytes by interacting with NCS-1 and the InsP3R","volume":"49","author":"Zhang","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"10.1124\/jpet.119.258178_bib42","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/FJC.0b013e31821458e8","article-title":"Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs","volume":"57","author":"Zhao","year":"2011","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524259243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524259243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.258178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:58:13Z","timestamp":1739980693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524259243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0022356524259243"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.258178","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.258178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}